DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)

Inclusion Criteria:

Patients who meet all of the following conditions are included.

• Patients aged ≥ 18 years and;

• Patients with chronic coronary syndrome, acute coronary syndrome without ST segmentelevation or acute coronary syndrome with elevation ST segment in non-culpritlesions 48 hours after the event and;

• Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significantno visible thrombus and;

• Patients who have been informed of the characteristics of the study and haveprovided their written informed consent.

Exclusion Criteria:

Patients who meet at least one of the following conditions are excluded:

• Patients with any contraindication for the administration of acetylcholine (ACh) ornitroglycerin (NTG).

• Patients with a history of coronary vasospasm or spontaneous dissection of thecoronary artery.

• Patients with significant medical, surgical or psychiatric condition that wouldaffect the safety of the subject or influence the outcome of the study according tothe doctor's opinion.

• Patients who received a combination of DES and DCB in the same vessel

• Patients with glomerular filtration rate <30 ml/min/ 1.73 m2

• Patients with body mass index >35 (may affect the evaluation qualitative diameter ofthe coronary artery).

• Patients with symptomatic congestive heart failure.

• Patients with significant autoimmune inflammatory conditions and patients takingimmunomodulatory medications (including methotrexate, cyclosporine, steroids).

• Patients with heart transplant.

• Patients with anemia (Hb <12 g/dL in men and <10 g/dL in women).

• Patients, women of childbearing age with a positive pregnancy test.

• Pregnant female patients.

• Patients included in other clinical trials with active follow-up.